Metastatic Disease of the Nervous System, Vol 149. Handbook of Clinical Neurology

  • ID: 4398538
  • Book
  • 304 Pages
  • Elsevier Science and Technology
1 of 4

Metastatic Disease of the Nervous System, Volume 149, begins with an overview of the impact and range of direct neoplastic involvement of the central and peripheral nervous system, comprehensively reviewing all aspects of brain metastases, from clinical, radiological and neuropathological manifestations, to the roles of surgery, radiation, systemic and palliative therapy in their management, and the complications of these interventions. The clinical manifestations, diagnosis and treatment of leptomeningeal, dural, spinal epidural and plexus metastases are also covered in detail.

  • Covers all aspects of brain metastases, from clinical, radiological and neuropathological manifestations, to the roles of surgery, radiation, systemic and palliative therapy
  • Presents a multidisciplinary review of the evidence regarding accuracy of diagnostic testing and evidence-based reviews of therapies
  • Addresses metastatic diseases of the nervous system for residents, fellows and clinicians in neurology and oncology
Note: Product cover images may vary from those shown
2 of 4

Section I. Overview 1. Overview of metastatic disease of the central nervous system

Section II. Brain Metastases 2. Brain metastases: Epidemiology 3. Pathogenesis and biology 4. Role of the blood-brain barrier in metastatic disease of the central nervous system 5. Metastatic diseases of the central nervous system
neuropathological aspects 6. Brain metastasis: Clinical manifestations, symptom management and palliative care 7. Brain metastases: Neuroimaging 8. The role of surgery for brain metastases from solid tumors 9. Brain metastases: Fractionated whole brain radiotherapy 10. Brain metastases: Radiosurgery 11. Systemic therapy for brain metastases 12. Neurocognitive aspects of brain metastasis

Section III. Other Nervous System Metastases 13. Leptomeningeal metastasis 14. Intracranial dural, calvarial and skull base metastases 15. Epidural and intramedullary spinal metastasis: Clinical features and role of fractionated radiotherapy 16. Management
spinal metastases 17. Plexus and peripheral nerve metastasis

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Schiff, David
Dr. Schiff and his colleagues have conducted several dozen clinical trials assessing new treatments for glioblastoma, anaplastic gliomas, low-grade gliomas, brain lymphomas, brain metastases, and meningiomas. These trials have included treatment with new cytotoxic chemotherapy drugs, signal transduction inhibitors, radiation sensitizers, brachytherapy and radiosurgery, anti-angiogenesis agents, differentiation agents, monoclonal antibodies, and targeted immunotoxins. A second research focus is the cause of gliomas and brain lymphoma. Dr. Schiff has studied risk factors for the development of brain lymphoma in patients with intact immune systems, including the association between organ transplantation and the subsequent development of glioma. Spinal cord disease in cancer patients is another area of ongoing research, in particular the diagnostic role of MRI and the optimal management of metastatic spinal disease.
Van den Bent, M J
Prof. dr. Martin J. van den Bent, MD is a trained neurologist, who started his career in neuro-oncology in the Erasmus MC Cancer Institute, Rotterdam, the Netherlands back in 1992, after finishing his neurology residency. His clinical interests are the treatment of primary brain tumors, and neurological complications of systemic cancers. He has published widely on these topics, and he is the principle investigator of many clinical studies including international large phase III studies on glioma. From 2003 to 2009 he was the chair of the EORTC Brain Tumor Group, and since 2012 he is a board member of the EORTC, the major European research organization on cancer. He is currently a board member of the European Association for Neuro-Oncology (EANO). He is also member of the core group of the response assessment in Neuro-Oncology (RANO) group, and active in the RANO brain metastases group. In 2015 he received the European CanCer Organisation (ECCO) Clinical Research Award.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll